Granted Patent
B2
US 12,251,395 · App. 17/942,698 · Granted Mar 18, 2025
RNAS for complement inhibition
Assignee:
Apellis Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
RNAs, such as miRNA and siRNA, and their use in treating complement-mediated disorders, are described.
Claims (7)
1. A method of inhibiting expression of C3 in a cell, the method comprising contacting the cell with an miRNA consisting of a nucleotide sequence at least 90% identical to any one of SEQ ID NOs: 76-77 or 79-85, or a portion thereof, wherein the nucleotide sequence is 19-23 nucleotides in length, or an siRNA comprising an antisense strand consisting of the nucleotide sequence.
2. The method of claim 1 , wherein the method comprises contacting the cell with a composition comprising a nucleic acid encoding the miRNA or siRNA.
3. The method of claim 2 , wherein the nucleic acid comprises any one of SEQ ID NOs: 86-87 or 89-115.
4. The method of claim 2 , wherein the composition comprises an expression vector comprising the nucleic acid.
5. The method of claim 4 , wherein the expression vector is a viral vector.
6. The method of claim 5 , wherein the viral vector is an adeno-associated viral (AAV) vector.
7. The method of claim 1 , wherein the cell is a hepatocyte.
Assignments (3)
RELEASE OF PATENT SECURITY AGREEMENT RECORDED AT REEL 067398 AND FRAME 0261
Recorded May 15, 2026
From: SIXTH STREET LENDING PARTNERS, IN ITS CAPACITY AS ADMINISTRATIVE AGENT
To: APELLIS PHARMACEUTICALS, INC.
Reel/Frame 075652/0212 →
SECURITY INTEREST
Recorded May 13, 2024
From: APELLIS PHARMACEUTICALS, INC.
To: SIXTH STREET LENDING PARTNERS
Reel/Frame 067398/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 7, 2023
From: MUELLER, CHRISTIAN; SCHEIBLER, LUKAS
To: APELLIS PHARMACEUTICALS, INC.
Reel/Frame 062906/0901 →
Continuity (3)
Division
16853732
· Apr 20, 2020
Provisional Application
62836412
· Apr 19, 2019
References Cited (90)
US 7427605B2
· Davis et al.
· 2008
[cited by applicant]
US 7582746B2
· Khvorova et al.
· 2009
[cited by applicant]
US 7888323B2
· Lambris et al.
· 2011
[cited by applicant]
US 8158601B2
· Chen et al.
· 2012
[cited by applicant]
US 8729041B2
· Mendell et al.
· 2014
[cited by applicant]
US 9012498B2
· Manoharan et al.
· 2015
[cited by applicant]
US 9062021B2
· Budzik et al.
· 2015
[cited by applicant]
US 9402816B2
· Colletti et al.
· 2016
[cited by applicant]
US 9415109B2
· Kumar et al.
· 2016
[cited by applicant]
US 20070178068A1
· Reich et al.
· 2007
[cited by applicant]
US 20090093425A1
· Dowdy et al.
· 2009
[cited by applicant]
US 20110190221A1
· Francois et al.
· 2011
[cited by applicant]
US 20120142763A1
· Dowdy et al.
· 2012
[cited by applicant]
US 20160194359A1
· Francois et al.
· 2016
[cited by applicant]
US 20230009757A1
· Francois
· 2023
[cited by applicant]
US 20230095695A1
· Hoßbach et al.
· 2023
[cited by applicant]
CN 105051057A
· 2015
[cited by applicant]
CN 105814205A
· 2016
[cited by applicant]
JP 2016505527A
· 2016
[cited by applicant]
RU 2474586C2
· 2013
[cited by applicant]
WO WO03066805A2
· 2003
[cited by applicant]
WO WO2007089375A2
· 2007
[cited by applicant]
WO WO2008097525A2
· 2008
[cited by applicant]
WO WO2012083046A2
· 2012
[cited by applicant]
WO WO2013036778A2
· 2013
[cited by applicant]
WO WO2014078731A2
· 2014
[cited by applicant]
WO WO2014078734A2
· 2014
[cited by applicant]
WO WO2014152391A1
· 2014
[cited by applicant]
WO WO2015089368A2
· 2015
[cited by applicant]
WO WO2017021385A1
· 2017
[cited by applicant]
WO WO2017055423A1
· 2017
[cited by applicant]
WO WO2017084987A1
· 2017
[cited by applicant]
WO WO2017178656A1
· 2017
[cited by applicant]
WO WO2018075373A1
· 2018
[cited by applicant]
WO WO2018215391A1
· 2018
[cited by applicant]
WO WO2019089922A1
· 2019
[cited by applicant]
WO WO2019145543A1
· 2019
[cited by applicant]
WO WO2020104669A1
· 2020
[cited by applicant]
WO WO2021037941A1
· 2021
[cited by applicant]
WO WO2021081026A1
· 2021
[cited by applicant]
WO WO2021163654A1
· 2021
[cited by applicant]
WO WO2021178607A1
· 2021
[cited by applicant]
WO WO2021163654A8
· 2021
[cited by applicant]
WO WO2022251484A1
· 2022
[cited by applicant]
WO WO2022251484A9
· 2023
[cited by applicant]
Kanasty, R. et al., Delivery materials for siRNA therapeutics, Nature Materials, 12(11):967-977 (2013).
[cited by applicant]
Bao, L. et al., Administration of a Soluble Recombinant Complement C3 Inhibitor Protects Against Renal Disease in MRL/Ipr Mice, J Am Soc Nephrol, 14:670-679 (2003).
[cited by applicant]
Broun et al., Catalytic Plasticity of Fatty Acid Modification Enzymes Underlying Chemical Diversity of Plant Lipids, Science, 282:1315-1317 (1998), abstract.
[cited by applicant]
Cho, M. et al., Autocrine Effect of Tumor-Derived Complement, Cell Rep., 6(6):1085-1095 (2014).
[cited by applicant]
Elliot, K. J. et al., ADAM17 silencing by adenovirus encoding miRNA-embedded siRNA revealed essential signal transduction by angiotensin II in vascular smooth muscle cells, Journal of Molecular and Cellular Cardiology, …
[cited by applicant]
Grossi, Federico, APL-1, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers, retrieved from Internet on Apr.…
[cited by applicant]
Han, X. et al., MicroRNA-130b Ameliorates Murine Lupus Nephritis Through Targeting the Type I Interferon Pathway on Renal Masangial Cells, Arthritis and Rheumatology, 68(9):2232-2243 (2016).
[cited by applicant]
International Search Report for PCT/US2017/56708 (Combination Therapy for C3 Inhibition, filed Oct. 16, 2017), issued by ISA/US, 4 pages (Jan. 18, 2018).
[cited by applicant]
International Search Report for PCT/US21/18071 (RNAS for Complement Inhibition, filed Feb. 13, 2021), received by ISA/US, 4 pages (Jun. 8, 2021).
[cited by applicant]
Karaki S. et al. Antisense Oligonucleotides, A Novel Developing Targeting Therapy, Antisense Therapy (2019).
[cited by applicant]
Lapidot, M. et al., Genome-wide natural antisense transcription: coupling its regulation to its different regulatory mechanisms, EMBO Rep., 7(12):1216-1222 (2006).
[cited by applicant]
Liu, X. et al., miR-130b promotes bladder cancer cell proliferation, migration and invasion by targeting VGLL4, Oncology Reports, 39:2324-2332 (2018).
[cited by applicant]
Ozcan, G. et al., Preclinical and clinical development of siRNA-based therapeutics, Advanced Drug Delivery Reviews, 87:108-119 (2015).
[cited by applicant]
Seffernick J. L. et al., Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different, Journal of Bacteriology, 183(8):2405-2410 (2001).
[cited by applicant]
Vega, Carolina, APL-2 and complement inhibition; a potential treatment of PNH and other complement-mediated diseases, retrieved from https://apellis.com/presentations/07c97663e2ad43e581dd4fdea522be63.pdf <https://protec…
[cited by applicant]
Witkowski, A. et al., Conversion of a β-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine, Biochemistry, 38:11643-11650 (1999).
[cited by applicant]
Written Opinion for PCT/US2017/56708 (Combination Therapy for C3 Inhibition, filed Oct. 16, 2017), issued by ISA/US, 8 pages (Jan. 18, 2018).
[cited by applicant]
Written Opinion for PCT/US21/18071 (RNAS for Complement Inhibition, filed Feb. 13, 2021), 4 pages (Jun. 8, 2021).
[cited by applicant]
Zheng, X. et al., Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene, Am J Transplant, 6(9):2099-108 (2006).
[cited by applicant]
Cheng, et al., Developement of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells, Gene. Ther., 19:375-384 (2012).
[cited by applicant]
Devalet, et al., Pathophsiology, diagnosis, and treatment of paraoxysmal nocturnal hemoglobinuria: a review, Eur. J. Haematol., 95:190-198 (2015).
[cited by applicant]
Lam, et al., siRNA versus as therapeutics for gene silencing, Molec. Ther. Nuc. Ac., 4:e252 (2015).
[cited by applicant]
De Jong, S. et al., Implications of genetic variation in the complement system in age-related macular degeneration, Progress in Retinal and Eye Research, 84:100952, 31 pages (2021).
[cited by applicant]
Hammond, S. et al., Delivery of oligonucleotide-based therapeutics: challenges and opportunities, EMBO Molecular Medicine, 13:e13243, 23 pages (2021).
[cited by applicant]
Hu, B. et al., Therapeutic siRNA: state of the art, Sig. Transduct. Target Ther., 5(101), 25 pages (2020).
[cited by applicant]
International Search Report for PCT/US22/31115, 5 pages (Sep. 23, 2022).
[cited by applicant]
Natoli, R. et al., Retinal Macrophages Synthesize C3 and Activate Complement in AMD and in Models of Focal Retinal Degeneration, Invest Ophthalmol Vis Sci., 58:2977-2990 (2017).
[cited by applicant]
Rutar, M. et al., Synthesis and Propagation of Complement C3 by Microglia/Monocytes in the Aging Retina, PLOS One, 9(4):e93343, 10 pages (2014).
[cited by applicant]
Schick, T. et al., Local complement activation in aqueous humor in patients with age-related macular degeneration, Eye, 31:810-813 (2017).
[cited by applicant]
Springer, A. and Dowdy, S., GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics, Nucleic Acid Therapeutics, 28(3): 109-118 (2018).
[cited by applicant]
Written Opinion for PCT/US22/31115, 4 pages (Sep. 23, 2022).
[cited by applicant]